Latest news
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20 - MoomooMoomoo · Fri, 07 Aug 2026 12:12:25 GMTARCT Looks 57.9% Overvalued on GF Value™ - GuruFocusGuruFocus · Fri, 07 Aug 2026 08:13:09 GMTArcturus Therapeutics Q2 2026 Earnings Call Transcript - MarketBeatMarketBeat · Thu, 06 Aug 2026 22:31:38 GMTArcturus Therapeutics Q2 Earnings Call Highlights - TradingViewTradingView · Thu, 06 Aug 2026 22:04:08 GMTArcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 21:20:02 GMTQ2 2026 Arcturus Therapeutics Holdings Inc Earnings Call Transcript - GuruFocusGuruFocus · Thu, 06 Aug 2026 20:30:00 GMTArcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress - Business WireBusiness Wire · Thu, 06 Aug 2026 20:01:00 GMTARCT 10-Q & SEC Filings - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 07:00:00 GMT